microRNA information: hsa-miR-222-3p
| Section | ID | link |
|---|---|---|
| Mature name: | hsa-miR-222-3p | miRbase |
| Accession: | MIMAT0000279 | miRbase |
| Precursor name: | hsa-mir-222 | miRbase |
| Precursor accession: | MI0000299 | miRbase |
| Symbol: | MIR222 | HGNC |
| RefSeq ID: | NR_029636 | GenBank |
| Sequence: | AGCUACAUCUGGCUACUGGGU |
Reported expression in cancers: hsa-miR-222-3p
| miRNA | cancer | regulation | reporting | PUBMED | method |
|---|---|---|---|---|---|
| hsa-miR-222-3p | bladder cancer | upregulation | "Increased expression of miR 222 is associated with ......" | 25078265 | |
| hsa-miR-222-3p | breast cancer | upregulation | "Forty-nine primary triple-negative breast cancer c ......" | 21270527 | qPCR |
| hsa-miR-222-3p | breast cancer | upregulation | "Among methods for profiling levels of miRNAs next- ......" | 22387599 | RNA-Seq; qPCR; Northern blot |
| hsa-miR-222-3p | breast cancer | upregulation | "Then five up-regulated miRNAs miR-100 miR-29a miR- ......" | 23994196 | |
| hsa-miR-222-3p | breast cancer | upregulation | "miR 222 induces Adriamycin resistance in breast ca ......" | 27699665 | |
| hsa-miR-222-3p | breast cancer | upregulation | "The aim of this study was to investigate the role ......" | 27746365 | qPCR |
| hsa-miR-222-3p | breast cancer | upregulation | "Through pathway enrichment analyses for miR-222 we ......" | 27746366 | qPCR |
| hsa-miR-222-3p | cervical and endocervical cancer | upregulation | "This study aimed to investigate the role of small ......" | 24895988 | |
| hsa-miR-222-3p | chordoma | downregulation | "miRNAs are small RNA sequences that affect transcr ......" | 23912551 | RNA-Seq; qPCR |
| hsa-miR-222-3p | colon cancer | downregulation | "To present proof-of-principle application for empl ......" | 23741026 | qPCR; Microarray |
| hsa-miR-222-3p | colorectal cancer | upregulation | "The increased expression of miR-200c miR-221 and m ......" | 21873159 | |
| hsa-miR-222-3p | gastric cancer | upregulation | "Here we showed that microRNA-222 miR-222 was up-re ......" | 22321642 | |
| hsa-miR-222-3p | gastric cancer | upregulation | "The expression levels of miR-20a miR-21 miR-25 miR ......" | 22996433 | qPCR |
| hsa-miR-222-3p | gastric cancer | upregulation | "The miRNAs differentially expressed in gastric can ......" | 24473397 | qPCR; Microarray |
| hsa-miR-222-3p | gastric cancer | upregulation | "Circulating miR 222 in plasma and its potential di ......" | 25129310 | qPCR |
| hsa-miR-222-3p | glioblastoma | upregulation | "MicroRNA miR-221 and miR-222 are frequently upregu ......" | 20428775 | |
| hsa-miR-222-3p | glioblastoma | upregulation | "MiR-221 and miR-222 miR-221/222 are frequently up- ......" | 20813046 | |
| hsa-miR-222-3p | liver cancer | downregulation | "This study was divided into four phases: I Ten can ......" | 22174818 | qPCR |
| hsa-miR-222-3p | liver cancer | downregulation | "Expression of microRNAs miR 21 miR 31 miR 122 miR ......" | 22213236 | qPCR |
| hsa-miR-222-3p | lung squamous cell cancer | upregulation | "MicroRNA 222 expression and its prognostic potenti ......" | 24955421 | Reverse transcription PCR |
| hsa-miR-222-3p | ovarian cancer | upregulation | "In the present study miR-222 was observed to be fr ......" | 24137356 | |
| hsa-miR-222-3p | ovarian cancer | upregulation | "Real-time quantitative PCR was used to determine t ......" | 25744846 | qPCR |
| hsa-miR-222-3p | ovarian cancer | upregulation | "Epithelial ovarian cancer secreted exosomal miR 22 ......" | 27172798 | |
| hsa-miR-222-3p | pancreatic cancer | upregulation | "Profiling of 95 microRNAs in pancreatic cancer cel ......" | 19030927 | qPCR |
| hsa-miR-222-3p | prostate cancer | upregulation | "The inhibition of the highly expressed miR 221 and ......" | 19107213 | |
| hsa-miR-222-3p | prostate cancer | upregulation | "Mir-221 and miR-222 two closely related miRNAs enc ......" | 21245048 | |
| hsa-miR-222-3p | thyroid cancer | upregulation | "Using laser microdissection followed by quantitati ......" | 23563786 | qPCR |
| hsa-miR-222-3p | thyroid cancer | upregulation | "To detect the levels of miRNA expression in fresh ......" | 23569392 | Microarray |
Reported cancer pathway affected by hsa-miR-222-3p
| miRNA | cancer | pathway | reporting | PUBMED | functional study |
|---|---|---|---|---|---|
| hsa-miR-222-3p | breast cancer | Apoptosis pathway | "Of the elevated miRNAs in ERalpha-negative cells m ......" | 18790736 | |
| hsa-miR-222-3p | breast cancer | Apoptosis pathway | "MiR 222 and miR 29a contribute to the drug resista ......" | 23994196 | Western blot |
| hsa-miR-222-3p | breast cancer | cell cycle pathway | "miRNA inhibitors specially targeting miR-221 or mi ......" | 24886939 | |
| hsa-miR-222-3p | breast cancer | Apoptosis pathway | "Exosomes from adriamycin resistant breast cancer c ......" | 26432333 | MTT assay |
| hsa-miR-222-3p | breast cancer | cell cycle pathway; Apoptosis pathway | "miR 222 confers the resistance of breast cancer ce ......" | 27282281 | Western blot; Flow cytometry |
| hsa-miR-222-3p | breast cancer | Apoptosis pathway | "miR 222 induces Adriamycin resistance in breast ca ......" | 27699665 | Western blot; Flow cytometry |
| hsa-miR-222-3p | chordoma | cell cycle pathway; Apoptosis pathway | "In this study miR-31 anti-miR-140-3p anti-miR148a ......" | 27016303 | Cell Proliferation Assay |
| hsa-miR-222-3p | colorectal cancer | Apoptosis pathway | "MiR 222 modulates multidrug resistance in human co ......" | 22677042 | Luciferase |
| hsa-miR-222-3p | endometrial cancer | cell cycle pathway | "The expression of miRNAs and related genes were de ......" | 23680357 | Western blot; Flow cytometry; Colony formation |
| hsa-miR-222-3p | endometrial cancer | cell cycle pathway | "Elevated MiR 222 3p promotes proliferation and inv ......" | 24498137 | |
| hsa-miR-222-3p | gastric cancer | cell cycle pathway; Apoptosis pathway | "MicroRNA 221 and microRNA 222 regulate gastric car ......" | 20618998 | Western blot; Luciferase |
| hsa-miR-222-3p | glioblastoma | cell cycle pathway | "Northern blot analysis was conducted to detect the ......" | 19953484 | Flow cytometry; Western blot |
| hsa-miR-222-3p | liver cancer | PI3K/Akt signaling pathway | "MiR 222 overexpression confers cell migratory adva ......" | 20103675 | Luciferase |
| hsa-miR-222-3p | liver cancer | cell cycle pathway | "MiR 222 overexpression promotes proliferation of h ......" | 24955159 | Flow cytometry; Western blot |
| hsa-miR-222-3p | lung cancer | PI3K/Akt signaling pathway | "High mobility group A1 proteins enhance the expres ......" | 21656127 | |
| hsa-miR-222-3p | lung cancer | cell cycle pathway | "Metformin inhibits lung cancer cells proliferation ......" | 23974492 | |
| hsa-miR-222-3p | lung squamous cell cancer | cell cycle pathway; Apoptosis pathway | "Growth inhibitory effects of miR 221 and miR 222 i ......" | 25641933 | |
| hsa-miR-222-3p | melanoma | cell cycle pathway | "Exosome mediated transfer of miR 222 is sufficient ......" | 26912358 | Western blot |
| hsa-miR-222-3p | ovarian cancer | cell cycle pathway | "MiR 221 and MiR 222 alterations in sporadic ovaria ......" | 20461750 | |
| hsa-miR-222-3p | pancreatic cancer | cell cycle pathway | "MicroRNA 222 Controls Human Pancreatic Cancer Cell ......" | 26535064 | Flow cytometry; Western blot |
| hsa-miR-222-3p | prostate cancer | cell cycle pathway | "miR 221 and miR 222 expression affects the prolife ......" | 17569667 | Colony formation |
| hsa-miR-222-3p | prostate cancer | cell cycle pathway | "The inhibition of the highly expressed miR 221 and ......" | 19107213 | |
| hsa-miR-222-3p | prostate cancer | cell cycle pathway; Apoptosis pathway | "Down regulation of mir 221 and mir 222 restrain pr ......" | 24892674 |
Reported cancer prognosis affected by hsa-miR-222-3p
| miRNA | cancer | prognosis | reporting | PUBMED | functional study |
|---|---|---|---|---|---|
| hsa-miR-222-3p | B cell lymphoma | poor survival; progression | "We measured the expression of each miRNA by quanti ......" | 21525173 | |
| hsa-miR-222-3p | bladder cancer | progression; poor survival; recurrence | "miR 143 miR 222 and miR 452 are useful as tumor st ......" | 22426337 | |
| hsa-miR-222-3p | bladder cancer | malignant trasformation | "We screened 723 miRNAs by microarray and selected ......" | 23945108 | |
| hsa-miR-222-3p | bladder cancer | worse prognosis; poor survival; staging | "Increased expression of miR 222 is associated with ......" | 25078265 | |
| hsa-miR-222-3p | bladder cancer | worse prognosis; drug resistance | "miR 222 attenuates cisplatin induced cell death by ......" | 26800397 | |
| hsa-miR-222-3p | breast cancer | drug resistance | "The drug resistance of MCF-7/ADR cells was evaluat ......" | 18971180 | Flow cytometry; MTT assay |
| hsa-miR-222-3p | breast cancer | poor survival | "Forty-nine primary triple-negative breast cancer c ......" | 21270527 | |
| hsa-miR-222-3p | breast cancer | cell migration | "We identified the microRNAs miRNAs miR-221 and miR ......" | 21673316 | |
| hsa-miR-222-3p | breast cancer | progression; drug resistance | "Here we find that nucleolin NCL a major nucleolar ......" | 23610125 | |
| hsa-miR-222-3p | breast cancer | drug resistance | "MiR 222 and miR 29a contribute to the drug resista ......" | 23994196 | Western blot |
| hsa-miR-222-3p | breast cancer | drug resistance | "MTT-cytotoxic miRNA microarray Real-time quantitat ......" | 25562151 | Western blot; Luciferase |
| hsa-miR-222-3p | breast cancer | drug resistance | "Exosomes from adriamycin resistant breast cancer c ......" | 26432333 | MTT assay |
| hsa-miR-222-3p | breast cancer | drug resistance | "miR 222 confers the resistance of breast cancer ce ......" | 27282281 | Western blot; Flow cytometry |
| hsa-miR-222-3p | breast cancer | poor survival | "In 5C 34 miRNAs of the DLK1-DIO3 locus and miR-31 ......" | 27659519 | |
| hsa-miR-222-3p | breast cancer | drug resistance; worse prognosis | "miR 222 induces Adriamycin resistance in breast ca ......" | 27699665 | Western blot; Flow cytometry |
| hsa-miR-222-3p | breast cancer | worse prognosis; drug resistance | "The aim of this study was to investigate the role ......" | 27746365 | |
| hsa-miR-222-3p | breast cancer | drug resistance; poor survival; worse prognosis | "MiR 222 promotes drug resistance of breast cancer ......" | 27746366 | Western blot |
| hsa-miR-222-3p | cervical and endocervical cancer | tumorigenesis | "MicroRNA 222 promotes the proliferation and migrat ......" | 24895988 | Western blot; Flow cytometry; Cell migration assay |
| hsa-miR-222-3p | chordoma | progression; differentiation | "In this study miR-31 anti-miR-140-3p anti-miR148a ......" | 27016303 | Cell Proliferation Assay |
| hsa-miR-222-3p | colon cancer | staging | "To present proof-of-principle application for empl ......" | 23741026 | |
| hsa-miR-222-3p | colorectal cancer | drug resistance | "MiR 222 modulates multidrug resistance in human co ......" | 22677042 | Luciferase |
| hsa-miR-222-3p | colorectal cancer | drug resistance | "On the other hand miR-222 targeting ADAM-17 a disi ......" | 23173124 | |
| hsa-miR-222-3p | colorectal cancer | staging; drug resistance | "To explore the potential molecular biomarkers pred ......" | 24460313 | |
| hsa-miR-222-3p | endometrial cancer | progression; metastasis; tumorigenesis | "The expression of miRNAs and related genes were de ......" | 23680357 | Western blot; Flow cytometry; Colony formation |
| hsa-miR-222-3p | endometrial cancer | drug resistance | "Elevated MiR 222 3p promotes proliferation and inv ......" | 24498137 | |
| hsa-miR-222-3p | gastric cancer | drug resistance; progression; malignant trasformation | "MicroRNA 221 and microRNA 222 regulate gastric car ......" | 20618998 | Western blot; Luciferase |
| hsa-miR-222-3p | gastric cancer | progression; tumorigenesis | "Increased miR 222 in H pylori associated gastric c ......" | 22321642 | Colony formation; RNAi |
| hsa-miR-222-3p | gastric cancer | poor survival; metastasis | "The expression levels of miR-20a miR-21 miR-25 miR ......" | 22996433 | |
| hsa-miR-222-3p | gastric cancer | poor survival; worse prognosis | "Circulating miR 222 in plasma and its potential di ......" | 25129310 | |
| hsa-miR-222-3p | glioblastoma | poor survival | "MiR 221 and miR 222 target PUMA to induce cell sur ......" | 20813046 | |
| hsa-miR-222-3p | glioblastoma | poor survival | "Thirty-nine and six microRNAs including hsa-miR-22 ......" | 21737610 | |
| hsa-miR-222-3p | glioblastoma | cell migration | "Furthermore miR-222 and -221 induced an increase i ......" | 21743492 | Colony formation |
| hsa-miR-222-3p | glioblastoma | differentiation | "Using this in vitro system a microarray-based high ......" | 24155920 | |
| hsa-miR-222-3p | glioblastoma | drug resistance | "In our study we found that radiation induced c-jun ......" | 24295494 | RNAi |
| hsa-miR-222-3p | liver cancer | malignant trasformation | "Our study identified and validated miR-224 overexp ......" | 18433021 | |
| hsa-miR-222-3p | liver cancer | malignant trasformation; staging; poor survival; motility | "MiR 222 overexpression confers cell migratory adva ......" | 20103675 | Luciferase |
| hsa-miR-222-3p | liver cancer | metastasis; tumorigenesis; recurrence | "We examined expression patterns of 4 microRNAs mic ......" | 21458843 | |
| hsa-miR-222-3p | liver cancer | worse prognosis; staging; tumor size; poor survival | "Expression of serum microRNAs miR 222 miR 181 miR ......" | 24124720 | |
| hsa-miR-222-3p | liver cancer | progression | "MiR 222 overexpression promotes proliferation of h ......" | 24955159 | Flow cytometry; Western blot |
| hsa-miR-222-3p | liver cancer | cell migration | "GNAI3 inhibits tumor cell migration and invasion a ......" | 25444921 | Transwell assay |
| hsa-miR-222-3p | lung cancer | progression | "Metformin inhibits lung cancer cells proliferation ......" | 23974492 | |
| hsa-miR-222-3p | lung squamous cell cancer | staging | "There was statistical difference in the serum leve ......" | 22009180 | |
| hsa-miR-222-3p | lung squamous cell cancer | tumorigenesis; drug resistance | "It has been recently reported that epidermal growt ......" | 24286402 | |
| hsa-miR-222-3p | lung squamous cell cancer | worse prognosis; poor survival | "MicroRNA 222 expression and its prognostic potenti ......" | 24955421 | |
| hsa-miR-222-3p | melanoma | progression; differentiation | "We have identified the promyelocytic leukemia zinc ......" | 18417445 | |
| hsa-miR-222-3p | melanoma | staging | "Constitutive activation of the ETS 1 miR 222 circu ......" | 21711453 | |
| hsa-miR-222-3p | melanoma | tumorigenesis | "Exosome mediated transfer of miR 222 is sufficient ......" | 26912358 | Western blot |
| hsa-miR-222-3p | ovarian cancer | poor survival | "MiR 221 and MiR 222 alterations in sporadic ovaria ......" | 20461750 | |
| hsa-miR-222-3p | ovarian cancer | tumorigenesis | "miR 222 is upregulated in epithelial ovarian cance ......" | 24137356 | Luciferase |
| hsa-miR-222-3p | pancreatic cancer | poor survival | "We measured the levels of miR-155 miR-203 miR-210 ......" | 19551852 | |
| hsa-miR-222-3p | pancreatic cancer | tumorigenesis | "miR-122 let-7 family and miR-101 are down-regulate ......" | 22303361 | |
| hsa-miR-222-3p | pancreatic cancer | worse prognosis | "Elevated expression of tumor miR 222 in pancreatic ......" | 24026657 | |
| hsa-miR-222-3p | prostate cancer | drug resistance | "The role of microRNA 221 and microRNA 222 in andro ......" | 19351832 | |
| hsa-miR-222-3p | prostate cancer | recurrence | "miR 21 miR 221 and miR 222 expression and prostate ......" | 23353719 | |
| hsa-miR-222-3p | prostate cancer | staging; progression | "Microarray and Q-RT-PCR analyses identified 43 miR ......" | 24583788 | |
| hsa-miR-222-3p | prostate cancer | progression; poor survival; cell migration | "Our present study of the microRNA miRNA expression ......" | 26325107 | |
| hsa-miR-222-3p | thyroid cancer | tumorigenesis | "MicroRNA miRNA microarray analysis has consistentl ......" | 18587330 | |
| hsa-miR-222-3p | thyroid cancer | metastasis; recurrence | "In this study we evaluated miRNA expression as a m ......" | 21537871 | |
| hsa-miR-222-3p | thyroid cancer | staging; metastasis; tumor size | "Genome-wide serum miRNA expression profiles were d ......" | 22472564 | |
| hsa-miR-222-3p | thyroid cancer | malignant trasformation | "A limited set of miRNA have been assessed as part ......" | 22771635 | |
| hsa-miR-222-3p | thyroid cancer | motility | "HMGB1 induces the overexpression of miR 222 and mi ......" | 23023232 | |
| hsa-miR-222-3p | thyroid cancer | tumor size; staging; metastasis | "To detect the levels of miRNA expression in fresh ......" | 23569392 | |
| hsa-miR-222-3p | thyroid cancer | recurrence | "MicroRNA 222 and microRNA 146b are tissue and circ ......" | 24301304 | |
| hsa-miR-222-3p | thyroid cancer | tumorigenesis | "Upregulation of miRNAs such as miR-146b miR-221 an ......" | 25202329 | |
| hsa-miR-222-3p | thyroid cancer | tumor size | "The levels of miR-146b miR-221 miR-222 and miR-155 ......" | 25456009 | |
| hsa-miR-222-3p | thyroid cancer | metastasis | "We performed small RNA deep-sequencing of 3 PTC th ......" | 26487287 | |
| hsa-miR-222-3p | thyroid cancer | tumor size | "All tumors were tested for the presence of the BRA ......" | 26950846 | |
| hsa-miR-222-3p | thyroid cancer | staging | "Likewise postoperative levels of miR-151-5p miR-22 ......" | 27162538 | |
| hsa-miR-222-3p | thyroid cancer | malignant trasformation | "We found that miR-146-5p miR-221-5p miR-222-3p miR ......" | 27586203 |
Reported gene related to hsa-miR-222-3p
| miRNA | cancer | gene | reporting | PUBMED |
|---|---|---|---|---|
| hsa-miR-222-3p | breast cancer | PTEN | "Moreover upregulation of miR-222 expression in MCF ......" | 27746366 |
| hsa-miR-222-3p | breast cancer | PTEN | "Western blot results suggested that miR-222 and -2 ......" | 23994196 |
| hsa-miR-222-3p | breast cancer | PTEN | "The results showed that inhibition of miR-222 in M ......" | 27699665 |
| hsa-miR-222-3p | cervical and endocervical cancer | PTEN | "The reduced the expression of PTEN and p27 by miR- ......" | 24895988 |
| hsa-miR-222-3p | gastric cancer | PTEN | "MicroRNA 221 and microRNA 222 regulate gastric car ......" | 20618998 |
| hsa-miR-222-3p | lung cancer | PTEN | "MiR-222 induces cell growth and cell cycle progres ......" | 23974492 |
| hsa-miR-222-3p | lung cancer | PTEN | "The expression of tumor suppressor p27 and PTEN mi ......" | 27566197 |
| hsa-miR-222-3p | pancreatic cancer | PTEN | "MiR-222 and putative target gene expression levels ......" | 26535064 |
| hsa-miR-222-3p | breast cancer | CDKN1B | "miR 222 confers the resistance of breast cancer ce ......" | 27282281 |
| hsa-miR-222-3p | cervical and endocervical cancer | CDKN1B | "MiR-222 plays an important role in the tumorigenes ......" | 24895988 |
| hsa-miR-222-3p | glioblastoma | CDKN1B | "Based on bioinformatic analysis we found that the ......" | 19953484 |
| hsa-miR-222-3p | melanoma | CDKN1B | "Besides microvesicle marker characterization we ev ......" | 26912358 |
| hsa-miR-222-3p | ovarian cancer | CDKN1B | "miR 222 is upregulated in epithelial ovarian cance ......" | 24137356 |
| hsa-miR-222-3p | ovarian cancer | CDKN1B | "MiR 221 and MiR 222 alterations in sporadic ovaria ......" | 20461750 |
| hsa-miR-222-3p | prostate cancer | CDKN1B | "miR 221 and miR 222 expression affects the prolife ......" | 17569667 |
| hsa-miR-222-3p | breast cancer | AKR1B1 | "The aim of this study was to explore the possible ......" | 27746366 |
| hsa-miR-222-3p | breast cancer | AKR1B1 | "Western blot results suggested that miR-222 and -2 ......" | 23994196 |
| hsa-miR-222-3p | breast cancer | AKR1B1 | "Importantly Adr resistance induced by miR-222 over ......" | 27699665 |
| hsa-miR-222-3p | breast cancer | AKR1B1 | "The results showed that downregulation of miR-222 ......" | 27282281 |
| hsa-miR-222-3p | bladder cancer | PPP2R2A | "miR-222 activated the Akt/mTOR pathway and inhibit ......" | 26800397 |
| hsa-miR-222-3p | liver cancer | PPP2R2A | "The protein phosphatase 2A subunit B PPP2R2A was p ......" | 20103675 |
| hsa-miR-222-3p | lung cancer | PPP2R2A | "Based on in silico prediction one of the putative ......" | 21656127 |
| hsa-miR-222-3p | gastric cancer | RECK | "Increased miR 222 in H pylori associated gastric c ......" | 22321642 |
| hsa-miR-222-3p | gastric cancer | RECK | "miR 221 and miR 222 Simultaneously Target RECK and ......" | 26364844 |
| hsa-miR-222-3p | colorectal cancer | ADAM17 | "MiR 222 modulates multidrug resistance in human co ......" | 22677042 |
| hsa-miR-222-3p | liver cancer | AFP | "According to the median fold change of miR-222 3-f ......" | 24124720 |
| hsa-miR-222-3p | breast cancer | ARHGEF7 | "In this study miR-146a and miR-222 were shown to b ......" | 26689540 |
| hsa-miR-222-3p | cervical and endocervical cancer | ARID1A | "MiR 221 and miR 222 simultaneously target ARID1A a ......" | 27160122 |
| hsa-miR-222-3p | breast cancer | ARID3A | "Individual miR-222 could be detected as bright pho ......" | 26432333 |
| hsa-miR-222-3p | glioblastoma | BBC3 | "MiR 221 and miR 222 target PUMA to induce cell sur ......" | 20813046 |
| hsa-miR-222-3p | ovarian cancer | CDKN1C | "miR-221 and miR-222 negatively regulate expression ......" | 20461750 |
| hsa-miR-222-3p | chordoma | CHDM | "In this study miR-31 anti-miR-140-3p anti-miR148a ......" | 27016303 |
| hsa-miR-222-3p | breast cancer | CYP19A1 | "Celecoxib increases miR 222 while deterring aromat ......" | 24923427 |
| hsa-miR-222-3p | breast cancer | DICER1 | "Addition of these miRNAs to ESR1+ cells reduces Di ......" | 21761362 |
| hsa-miR-222-3p | melanoma | ETS1 | "Constitutive activation of the ETS 1 miR 222 circu ......" | 21711453 |
| hsa-miR-222-3p | breast cancer | FOXO1 | "RT-qPCR and Western blot results showed that miR-2 ......" | 27746366 |
| hsa-miR-222-3p | liver cancer | GNAI3 | "GNAI3 inhibits tumor cell migration and invasion a ......" | 25444921 |
| hsa-miR-222-3p | thyroid cancer | HGF | "Finally miR-296 and miR-222 levels negatively corr ......" | 19926710 |
| hsa-miR-222-3p | lung cancer | HMGA1 | "Here we showed that in a cohort of non-small cell ......" | 21656127 |
| hsa-miR-222-3p | thyroid cancer | HMGB1 | "HMGB1 induces the overexpression of miR 222 and mi ......" | 23023232 |
| hsa-miR-222-3p | kidney renal cell cancer | LARP6 | "Gain of function experiments showed that miR-221 a ......" | 26201448 |
| hsa-miR-222-3p | melanoma | PML | "We have identified the promyelocytic leukemia zinc ......" | 18417445 |
| hsa-miR-222-3p | breast cancer | QRSL1 | "In breast cancer the microRNAs miRNAs miR-221 and ......" | 23776679 |
| hsa-miR-222-3p | colorectal cancer | RELA | "Human CRC tissues had higher levels of miR-221 and ......" | 24931456 |
| hsa-miR-222-3p | prostate cancer | SIRT1 | "Down regulation of mir 221 and mir 222 restrain pr ......" | 24892674 |
| hsa-miR-222-3p | ovarian cancer | SOCS3 | "Luciferase assay verified miR-222-3p targeted SOCS ......" | 27172798 |
| hsa-miR-222-3p | colorectal cancer | STAT3 | "We investigated whether microRNA miR-221 and miR-2 ......" | 24931456 |
| hsa-miR-222-3p | breast cancer | TRPS1 | "In breast cancer the microRNAs miRNAs miR-221 and ......" | 23776679 |
| hsa-miR-222-3p | thyroid cancer | TXK | "Finally miR-296 and miR-222 levels negatively corr ......" | 19926710 |
| hsa-miR-222-3p | gastric cancer | VGLL4 | "Here we confirmed the suppressor role of VGLL4 on ......" | 26045994 |
Expression profile in cancer corhorts:
Putative target regulations
| miRNA | Gene | Cancer | Interaction | Correlation beta |
|---|---|---|---|---|
hsa-miR-222-3p | ATP7B | 13 cancers: BLCA; BRCA; CESC; HNSC; KIRC; LGG; LIHC; LUAD; LUSC; OV; PRAD; SARC; THCA | miRNAWalker2 validate | TCGA BLCA -0.242; TCGA BRCA -0.398; TCGA CESC -0.914; TCGA HNSC -0.184; TCGA KIRC -0.222; TCGA LGG -0.06; TCGA LIHC -0.143; TCGA LUAD -0.403; TCGA LUSC -0.268; TCGA OV -0.228; TCGA PRAD -0.27; TCGA SARC -0.132; TCGA THCA -0.272 |
hsa-miR-222-3p | BPTF | 10 cancers: BLCA; CESC; COAD; HNSC; KIRP; LGG; LUAD; PRAD; SARC; THCA | miRNAWalker2 validate | TCGA BLCA -0.087; TCGA CESC -0.1; TCGA COAD -0.103; TCGA HNSC -0.064; TCGA KIRP -0.093; TCGA LGG -0.106; TCGA LUAD -0.084; TCGA PRAD -0.097; TCGA SARC -0.123; TCGA THCA -0.059 |
hsa-miR-222-3p | CASC3 | 11 cancers: BLCA; CESC; HNSC; LGG; LUAD; LUSC; OV; PAAD; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.069; TCGA CESC -0.122; TCGA HNSC -0.078; TCGA LGG -0.146; TCGA LUAD -0.084; TCGA LUSC -0.128; TCGA OV -0.146; TCGA PAAD -0.082; TCGA SARC -0.088; TCGA STAD -0.075; TCGA UCEC -0.083 |
hsa-miR-222-3p | CASKIN2 | 10 cancers: BLCA; BRCA; CESC; HNSC; KIRC; LGG; LIHC; PAAD; SARC; STAD | miRNAWalker2 validate | TCGA BLCA -0.133; TCGA BRCA -0.084; TCGA CESC -0.095; TCGA HNSC -0.073; TCGA KIRC -0.171; TCGA LGG -0.127; TCGA LIHC -0.065; TCGA PAAD -0.138; TCGA SARC -0.11; TCGA STAD -0.112 |
hsa-miR-222-3p | CDKN1B | 12 cancers: BLCA; BRCA; CESC; COAD; HNSC; KIRC; LGG; LIHC; LUSC; OV; SARC; STAD | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | TCGA BLCA -0.083; TCGA BRCA -0.072; TCGA CESC -0.203; TCGA COAD -0.098; TCGA HNSC -0.149; TCGA KIRC -0.163; TCGA LGG -0.106; TCGA LIHC -0.14; TCGA LUSC -0.152; TCGA OV -0.172; TCGA SARC -0.202; TCGA STAD -0.112 |
hsa-miR-222-3p | CDKN1C | 10 cancers: BLCA; CESC; ESCA; HNSC; KIRC; KIRP; LUSC; OV; SARC; STAD | miRNAWalker2 validate; miRTarBase; miRNATAP | TCGA BLCA -0.246; TCGA CESC -0.237; TCGA ESCA -0.367; TCGA HNSC -0.284; TCGA KIRC -0.22; TCGA KIRP -0.29; TCGA LUSC -0.454; TCGA OV -0.226; TCGA SARC -0.326; TCGA STAD -0.403 |
hsa-miR-222-3p | EEF2 | 10 cancers: BLCA; BRCA; ESCA; HNSC; LGG; PAAD; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.052; TCGA BRCA -0.106; TCGA ESCA -0.179; TCGA HNSC -0.142; TCGA LGG -0.179; TCGA PAAD -0.141; TCGA PRAD -0.201; TCGA SARC -0.103; TCGA STAD -0.101; TCGA UCEC -0.103 |
hsa-miR-222-3p | FBXO21 | 9 cancers: BLCA; BRCA; CESC; ESCA; HNSC; LGG; LUAD; PAAD; SARC | miRNAWalker2 validate | TCGA BLCA -0.117; TCGA BRCA -0.052; TCGA CESC -0.109; TCGA ESCA -0.067; TCGA HNSC -0.067; TCGA LGG -0.064; TCGA LUAD -0.17; TCGA PAAD -0.176; TCGA SARC -0.177 |
hsa-miR-222-3p | KIF5C | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; LUAD; LUSC; PAAD; PRAD; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.727; TCGA BRCA -0.386; TCGA CESC -0.289; TCGA COAD -0.55; TCGA ESCA -0.493; TCGA HNSC -0.285; TCGA KIRC -0.128; TCGA LUAD -0.399; TCGA LUSC -0.516; TCGA PAAD -0.648; TCGA PRAD -0.192; TCGA SARC -0.464; TCGA THCA -0.312; TCGA STAD -0.552 |
hsa-miR-222-3p | KIT | 11 cancers: BLCA; CESC; COAD; ESCA; HNSC; LUAD; LUSC; OV; PAAD; THCA; STAD | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | TCGA BLCA -0.472; TCGA CESC -0.477; TCGA COAD -0.686; TCGA ESCA -0.502; TCGA HNSC -0.653; TCGA LUAD -0.89; TCGA LUSC -0.818; TCGA OV -0.264; TCGA PAAD -0.375; TCGA THCA -0.886; TCGA STAD -0.696 |
hsa-miR-222-3p | OAZ2 | 11 cancers: BLCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; PAAD; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.055; TCGA CESC -0.072; TCGA COAD -0.069; TCGA ESCA -0.059; TCGA HNSC -0.106; TCGA LIHC -0.139; TCGA LUAD -0.111; TCGA PAAD -0.147; TCGA SARC -0.074; TCGA THCA -0.05; TCGA STAD -0.105 |
hsa-miR-222-3p | PAIP2 | 14 cancers: BLCA; CESC; ESCA; KIRC; KIRP; LIHC; LUAD; LUSC; OV; PAAD; PRAD; SARC; THCA; STAD | miRNAWalker2 validate; MirTarget | TCGA BLCA -0.066; TCGA CESC -0.083; TCGA ESCA -0.087; TCGA KIRC -0.119; TCGA KIRP -0.055; TCGA LIHC -0.053; TCGA LUAD -0.094; TCGA LUSC -0.135; TCGA OV -0.099; TCGA PAAD -0.147; TCGA PRAD -0.08; TCGA SARC -0.089; TCGA THCA -0.163; TCGA STAD -0.175 |
hsa-miR-222-3p | PAN2 | 12 cancers: BLCA; BRCA; CESC; KIRC; KIRP; LGG; LIHC; LUAD; OV; PRAD; SARC; THCA | miRNAWalker2 validate | TCGA BLCA -0.287; TCGA BRCA -0.121; TCGA CESC -0.162; TCGA KIRC -0.135; TCGA KIRP -0.286; TCGA LGG -0.118; TCGA LIHC -0.148; TCGA LUAD -0.172; TCGA OV -0.136; TCGA PRAD -0.122; TCGA SARC -0.109; TCGA THCA -0.103 |
hsa-miR-222-3p | PDXDC1 | 9 cancers: BLCA; BRCA; CESC; HNSC; KIRC; LIHC; LUAD; PRAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.13; TCGA BRCA -0.132; TCGA CESC -0.238; TCGA HNSC -0.077; TCGA KIRC -0.051; TCGA LIHC -0.236; TCGA LUAD -0.129; TCGA PRAD -0.208; TCGA UCEC -0.13 |
hsa-miR-222-3p | PEBP1 | 11 cancers: BLCA; BRCA; KIRC; KIRP; LIHC; LUAD; OV; PAAD; PRAD; THCA; UCEC | miRNAWalker2 validate | TCGA BLCA -0.265; TCGA BRCA -0.057; TCGA KIRC -0.215; TCGA KIRP -0.111; TCGA LIHC -0.336; TCGA LUAD -0.117; TCGA OV -0.075; TCGA PAAD -0.2; TCGA PRAD -0.064; TCGA THCA -0.119; TCGA UCEC -0.052 |
hsa-miR-222-3p | PELI2 | 11 cancers: BLCA; COAD; HNSC; KIRP; LGG; LIHC; LUAD; PAAD; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.168; TCGA COAD -0.268; TCGA HNSC -0.503; TCGA KIRP -0.145; TCGA LGG -0.222; TCGA LIHC -0.19; TCGA LUAD -0.37; TCGA PAAD -0.165; TCGA SARC -0.206; TCGA THCA -0.168; TCGA STAD -0.103 |
hsa-miR-222-3p | PPM1H | 10 cancers: BLCA; BRCA; CESC; HNSC; LUAD; OV; PAAD; PRAD; THCA; UCEC | miRNAWalker2 validate | TCGA BLCA -0.586; TCGA BRCA -0.14; TCGA CESC -0.95; TCGA HNSC -0.667; TCGA LUAD -0.289; TCGA OV -0.269; TCGA PAAD -0.202; TCGA PRAD -0.3; TCGA THCA -0.208; TCGA UCEC -0.229 |
hsa-miR-222-3p | SELE | 9 cancers: BLCA; COAD; ESCA; HNSC; LIHC; LUSC; PAAD; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.365; TCGA COAD -0.647; TCGA ESCA -0.44; TCGA HNSC -0.733; TCGA LIHC -0.52; TCGA LUSC -0.672; TCGA PAAD -0.579; TCGA THCA -0.173; TCGA STAD -0.331 |
hsa-miR-222-3p | SLC25A36 | 9 cancers: BLCA; CESC; KIRP; LGG; LUAD; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.103; TCGA CESC -0.065; TCGA KIRP -0.148; TCGA LGG -0.082; TCGA LUAD -0.08; TCGA PRAD -0.119; TCGA THCA -0.064; TCGA STAD -0.105; TCGA UCEC -0.115 |
hsa-miR-222-3p | SORT1 | 9 cancers: BLCA; CESC; COAD; HNSC; LUAD; LUSC; PAAD; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.177; TCGA CESC -0.299; TCGA COAD -0.141; TCGA HNSC -0.435; TCGA LUAD -0.077; TCGA LUSC -0.273; TCGA PAAD -0.182; TCGA THCA -0.057; TCGA STAD -0.125 |
hsa-miR-222-3p | STOX2 | 9 cancers: BLCA; COAD; ESCA; HNSC; KIRC; KIRP; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.27; TCGA COAD -0.729; TCGA ESCA -0.336; TCGA HNSC -0.381; TCGA KIRC -0.293; TCGA KIRP -0.307; TCGA SARC -0.475; TCGA THCA -0.288; TCGA STAD -0.428 |
hsa-miR-222-3p | TCEAL1 | 10 cancers: BLCA; BRCA; CESC; ESCA; HNSC; PAAD; SARC; THCA; STAD; UCEC | miRNAWalker2 validate; miRTarBase | TCGA BLCA -0.237; TCGA BRCA -0.28; TCGA CESC -0.093; TCGA ESCA -0.202; TCGA HNSC -0.123; TCGA PAAD -0.285; TCGA SARC -0.17; TCGA THCA -0.051; TCGA STAD -0.345; TCGA UCEC -0.11 |
hsa-miR-222-3p | TNRC6B | 10 cancers: BLCA; CESC; ESCA; HNSC; KIRP; LGG; PRAD; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.072; TCGA CESC -0.1; TCGA ESCA -0.11; TCGA HNSC -0.146; TCGA KIRP -0.191; TCGA LGG -0.086; TCGA PRAD -0.1; TCGA SARC -0.074; TCGA THCA -0.083; TCGA STAD -0.147 |
hsa-miR-222-3p | WDR6 | 10 cancers: BLCA; BRCA; CESC; KIRP; LGG; LUAD; OV; PRAD; SARC; UCEC | miRNAWalker2 validate | TCGA BLCA -0.205; TCGA BRCA -0.137; TCGA CESC -0.121; TCGA KIRP -0.106; TCGA LGG -0.154; TCGA LUAD -0.051; TCGA OV -0.096; TCGA PRAD -0.066; TCGA SARC -0.143; TCGA UCEC -0.073 |
hsa-miR-222-3p | ZFYVE16 | 15 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; LUAD; LUSC; OV; PRAD; SARC; THCA; STAD; UCEC | miRNAWalker2 validate; MirTarget | TCGA BLCA -0.131; TCGA BRCA -0.129; TCGA CESC -0.131; TCGA COAD -0.108; TCGA ESCA -0.072; TCGA HNSC -0.062; TCGA LGG -0.107; TCGA LUAD -0.08; TCGA LUSC -0.196; TCGA OV -0.106; TCGA PRAD -0.169; TCGA SARC -0.143; TCGA THCA -0.055; TCGA STAD -0.096; TCGA UCEC -0.071 |
hsa-miR-222-3p | ZFYVE9 | 11 cancers: BLCA; COAD; ESCA; KIRC; LIHC; LUAD; OV; PAAD; PRAD; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.133; TCGA COAD -0.076; TCGA ESCA -0.149; TCGA KIRC -0.093; TCGA LIHC -0.111; TCGA LUAD -0.149; TCGA OV -0.097; TCGA PAAD -0.203; TCGA PRAD -0.073; TCGA THCA -0.18; TCGA STAD -0.142 |
hsa-miR-222-3p | ZMYND11 | 13 cancers: BLCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LUAD; PAAD; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.185; TCGA CESC -0.134; TCGA COAD -0.116; TCGA ESCA -0.121; TCGA HNSC -0.094; TCGA KIRC -0.07; TCGA KIRP -0.068; TCGA LGG -0.105; TCGA LUAD -0.131; TCGA PAAD -0.16; TCGA SARC -0.133; TCGA THCA -0.12; TCGA STAD -0.224 |
hsa-miR-222-3p | ZNF708 | 12 cancers: BLCA; CESC; HNSC; LGG; LUSC; OV; PAAD; PRAD; SARC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.28; TCGA CESC -0.265; TCGA HNSC -0.106; TCGA LGG -0.107; TCGA LUSC -0.136; TCGA OV -0.156; TCGA PAAD -0.143; TCGA PRAD -0.168; TCGA SARC -0.122; TCGA THCA -0.11; TCGA STAD -0.142; TCGA UCEC -0.071 |
hsa-miR-222-3p | MEGF9 | 10 cancers: BLCA; BRCA; COAD; ESCA; HNSC; LIHC; LUSC; PAAD; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.116; TCGA BRCA -0.191; TCGA COAD -0.168; TCGA ESCA -0.247; TCGA HNSC -0.16; TCGA LIHC -0.173; TCGA LUSC -0.208; TCGA PAAD -0.176; TCGA STAD -0.212; TCGA UCEC -0.165 |
hsa-miR-222-3p | RBM24 | 11 cancers: BLCA; BRCA; CESC; ESCA; HNSC; LUSC; PAAD; SARC; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.191; TCGA BRCA -0.302; TCGA CESC -0.452; TCGA ESCA -0.73; TCGA HNSC -0.765; TCGA LUSC -0.655; TCGA PAAD -0.272; TCGA SARC -0.566; TCGA THCA -0.47; TCGA STAD -0.997; TCGA UCEC -0.236 |
hsa-miR-222-3p | ZNF74 | 9 cancers: BLCA; CESC; HNSC; LGG; LUAD; OV; PAAD; PRAD; SARC | MirTarget | TCGA BLCA -0.148; TCGA CESC -0.11; TCGA HNSC -0.136; TCGA LGG -0.21; TCGA LUAD -0.144; TCGA OV -0.077; TCGA PAAD -0.125; TCGA PRAD -0.204; TCGA SARC -0.103 |
hsa-miR-222-3p | MYLIP | 16 cancers: BLCA; BRCA; CESC; COAD; HNSC; KIRC; KIRP; LGG; LUAD; OV; PAAD; PRAD; SARC; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.487; TCGA BRCA -0.17; TCGA CESC -0.226; TCGA COAD -0.189; TCGA HNSC -0.265; TCGA KIRC -0.24; TCGA KIRP -0.185; TCGA LGG -0.064; TCGA LUAD -0.22; TCGA OV -0.098; TCGA PAAD -0.17; TCGA PRAD -0.14; TCGA SARC -0.142; TCGA THCA -0.071; TCGA STAD -0.196; TCGA UCEC -0.178 |
hsa-miR-222-3p | RSBN1L | 10 cancers: BLCA; COAD; HNSC; KIRP; LGG; PRAD; SARC; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.081; TCGA COAD -0.108; TCGA HNSC -0.105; TCGA KIRP -0.12; TCGA LGG -0.064; TCGA PRAD -0.053; TCGA SARC -0.092; TCGA THCA -0.08; TCGA STAD -0.085; TCGA UCEC -0.079 |
hsa-miR-222-3p | ZFP30 | 11 cancers: BLCA; CESC; ESCA; HNSC; KIRC; OV; PAAD; PRAD; SARC; THCA; STAD | MirTarget | TCGA BLCA -0.211; TCGA CESC -0.238; TCGA ESCA -0.315; TCGA HNSC -0.118; TCGA KIRC -0.095; TCGA OV -0.138; TCGA PAAD -0.132; TCGA PRAD -0.157; TCGA SARC -0.122; TCGA THCA -0.071; TCGA STAD -0.222 |
hsa-miR-222-3p | SCN11A | 9 cancers: BLCA; COAD; ESCA; KIRC; KIRP; LGG; OV; PAAD; STAD | MirTarget | TCGA BLCA -0.446; TCGA COAD -0.737; TCGA ESCA -0.491; TCGA KIRC -0.182; TCGA KIRP -0.578; TCGA LGG -0.115; TCGA OV -0.31; TCGA PAAD -0.521; TCGA STAD -0.755 |
hsa-miR-222-3p | NSMCE4A | 9 cancers: BLCA; LGG; LIHC; LUAD; OV; PAAD; PRAD; THCA; UCEC | MirTarget | TCGA BLCA -0.068; TCGA LGG -0.104; TCGA LIHC -0.083; TCGA LUAD -0.129; TCGA OV -0.1; TCGA PAAD -0.091; TCGA PRAD -0.081; TCGA THCA -0.051; TCGA UCEC -0.079 |
hsa-miR-222-3p | PIK3R1 | 13 cancers: BLCA; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; OV; PAAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.122; TCGA COAD -0.203; TCGA ESCA -0.285; TCGA HNSC -0.324; TCGA KIRC -0.107; TCGA KIRP -0.211; TCGA LGG -0.133; TCGA LIHC -0.257; TCGA OV -0.211; TCGA PAAD -0.135; TCGA SARC -0.19; TCGA STAD -0.271; TCGA UCEC -0.409 |
hsa-miR-222-3p | CLGN | 9 cancers: BLCA; BRCA; CESC; HNSC; LGG; LUAD; PAAD; PRAD; STAD | MirTarget | TCGA BLCA -0.197; TCGA BRCA -0.792; TCGA CESC -0.828; TCGA HNSC -0.755; TCGA LGG -0.36; TCGA LUAD -0.461; TCGA PAAD -0.672; TCGA PRAD -0.202; TCGA STAD -0.789 |
hsa-miR-222-3p | PCMTD1 | 14 cancers: BLCA; CESC; COAD; ESCA; HNSC; LGG; LIHC; LUAD; LUSC; PRAD; SARC; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.23; TCGA CESC -0.149; TCGA COAD -0.178; TCGA ESCA -0.108; TCGA HNSC -0.092; TCGA LGG -0.056; TCGA LIHC -0.083; TCGA LUAD -0.115; TCGA LUSC -0.104; TCGA PRAD -0.062; TCGA SARC -0.188; TCGA THCA -0.172; TCGA STAD -0.259; TCGA UCEC -0.102 |
hsa-miR-222-3p | LUZP2 | 9 cancers: BLCA; BRCA; COAD; HNSC; KIRC; LGG; PRAD; STAD; UCEC | MirTarget | TCGA BLCA -0.411; TCGA BRCA -0.418; TCGA COAD -0.818; TCGA HNSC -0.829; TCGA KIRC -0.393; TCGA LGG -0.378; TCGA PRAD -0.46; TCGA STAD -0.515; TCGA UCEC -0.268 |
hsa-miR-222-3p | TCF12 | 10 cancers: BLCA; CESC; HNSC; LGG; LUAD; LUSC; OV; SARC; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.058; TCGA CESC -0.193; TCGA HNSC -0.153; TCGA LGG -0.362; TCGA LUAD -0.118; TCGA LUSC -0.198; TCGA OV -0.063; TCGA SARC -0.088; TCGA STAD -0.111; TCGA UCEC -0.068 |
hsa-miR-222-3p | FNDC3A | 13 cancers: BLCA; CESC; COAD; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; OV; PAAD; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.08; TCGA CESC -0.243; TCGA COAD -0.154; TCGA HNSC -0.118; TCGA KIRC -0.07; TCGA KIRP -0.152; TCGA LIHC -0.143; TCGA LUAD -0.151; TCGA LUSC -0.288; TCGA OV -0.136; TCGA PAAD -0.166; TCGA THCA -0.051; TCGA STAD -0.083 |
hsa-miR-222-3p | ZNF275 | 10 cancers: BLCA; CESC; HNSC; LGG; LIHC; LUAD; PAAD; PRAD; THCA; STAD | MirTarget | TCGA BLCA -0.114; TCGA CESC -0.19; TCGA HNSC -0.182; TCGA LGG -0.207; TCGA LIHC -0.088; TCGA LUAD -0.115; TCGA PAAD -0.154; TCGA PRAD -0.089; TCGA THCA -0.158; TCGA STAD -0.055 |
hsa-miR-222-3p | KIAA0430 | 10 cancers: BLCA; CESC; COAD; ESCA; HNSC; KIRC; LIHC; LUAD; SARC; STAD | MirTarget; miRNATAP | TCGA BLCA -0.138; TCGA CESC -0.072; TCGA COAD -0.173; TCGA ESCA -0.131; TCGA HNSC -0.062; TCGA KIRC -0.1; TCGA LIHC -0.095; TCGA LUAD -0.081; TCGA SARC -0.074; TCGA STAD -0.186 |
hsa-miR-222-3p | ZNF181 | 11 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRC; PAAD; PRAD; SARC; THCA; STAD | MirTarget | TCGA BLCA -0.199; TCGA BRCA -0.059; TCGA CESC -0.107; TCGA ESCA -0.107; TCGA HNSC -0.143; TCGA KIRC -0.091; TCGA PAAD -0.229; TCGA PRAD -0.166; TCGA SARC -0.135; TCGA THCA -0.115; TCGA STAD -0.208 |
hsa-miR-222-3p | NLK | 10 cancers: BLCA; BRCA; CESC; KIRP; LUAD; LUSC; OV; PAAD; PRAD; THCA | MirTarget; miRNATAP | TCGA BLCA -0.162; TCGA BRCA -0.088; TCGA CESC -0.141; TCGA KIRP -0.074; TCGA LUAD -0.103; TCGA LUSC -0.109; TCGA OV -0.143; TCGA PAAD -0.074; TCGA PRAD -0.122; TCGA THCA -0.086 |
hsa-miR-222-3p | POGZ | 11 cancers: BLCA; BRCA; CESC; HNSC; KIRC; LGG; LUAD; OV; PRAD; SARC; STAD | MirTarget; miRNATAP | TCGA BLCA -0.154; TCGA BRCA -0.062; TCGA CESC -0.165; TCGA HNSC -0.086; TCGA KIRC -0.072; TCGA LGG -0.113; TCGA LUAD -0.152; TCGA OV -0.12; TCGA PRAD -0.134; TCGA SARC -0.17; TCGA STAD -0.083 |
hsa-miR-222-3p | SYBU | 11 cancers: BLCA; BRCA; CESC; HNSC; LIHC; LUAD; PAAD; PRAD; SARC; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.273; TCGA BRCA -0.38; TCGA CESC -0.577; TCGA HNSC -0.401; TCGA LIHC -0.625; TCGA LUAD -0.232; TCGA PAAD -0.435; TCGA PRAD -0.19; TCGA SARC -0.357; TCGA THCA -0.33; TCGA STAD -0.224 |
hsa-miR-222-3p | TMEM25 | 10 cancers: BLCA; BRCA; COAD; ESCA; HNSC; KIRP; LIHC; PAAD; SARC; STAD | MirTarget | TCGA BLCA -0.277; TCGA BRCA -0.293; TCGA COAD -0.279; TCGA ESCA -0.26; TCGA HNSC -0.209; TCGA KIRP -0.19; TCGA LIHC -0.594; TCGA PAAD -0.2; TCGA SARC -0.387; TCGA STAD -0.478 |
hsa-miR-222-3p | ZNF91 | 12 cancers: BLCA; BRCA; CESC; COAD; HNSC; LGG; PAAD; PRAD; SARC; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.353; TCGA BRCA -0.212; TCGA CESC -0.262; TCGA COAD -0.082; TCGA HNSC -0.188; TCGA LGG -0.084; TCGA PAAD -0.093; TCGA PRAD -0.143; TCGA SARC -0.166; TCGA THCA -0.132; TCGA STAD -0.087; TCGA UCEC -0.072 |
hsa-miR-222-3p | VGLL4 | 9 cancers: BLCA; CESC; COAD; HNSC; KIRP; LGG; OV; THCA; UCEC | MirTarget | TCGA BLCA -0.065; TCGA CESC -0.102; TCGA COAD -0.074; TCGA HNSC -0.148; TCGA KIRP -0.207; TCGA LGG -0.07; TCGA OV -0.056; TCGA THCA -0.058; TCGA UCEC -0.092 |
hsa-miR-222-3p | CDK19 | 11 cancers: BLCA; CESC; COAD; HNSC; KIRC; KIRP; LUSC; OV; PRAD; SARC; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.113; TCGA CESC -0.077; TCGA COAD -0.127; TCGA HNSC -0.077; TCGA KIRC -0.116; TCGA KIRP -0.074; TCGA LUSC -0.099; TCGA OV -0.117; TCGA PRAD -0.384; TCGA SARC -0.1; TCGA UCEC -0.06 |
hsa-miR-222-3p | ZC3H13 | 10 cancers: BLCA; CESC; COAD; HNSC; LIHC; LUAD; LUSC; SARC; THCA; STAD | MirTarget | TCGA BLCA -0.106; TCGA CESC -0.098; TCGA COAD -0.138; TCGA HNSC -0.081; TCGA LIHC -0.134; TCGA LUAD -0.076; TCGA LUSC -0.168; TCGA SARC -0.14; TCGA THCA -0.06; TCGA STAD -0.15 |
hsa-miR-222-3p | PHF2 | 11 cancers: BLCA; BRCA; COAD; ESCA; HNSC; LGG; LUAD; LUSC; PRAD; SARC; STAD | MirTarget; miRNATAP | TCGA BLCA -0.074; TCGA BRCA -0.058; TCGA COAD -0.133; TCGA ESCA -0.105; TCGA HNSC -0.079; TCGA LGG -0.126; TCGA LUAD -0.068; TCGA LUSC -0.079; TCGA PRAD -0.105; TCGA SARC -0.101; TCGA STAD -0.16 |
hsa-miR-222-3p | GUCY1A2 | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; LUSC; PAAD; THCA; STAD | MirTarget | TCGA BLCA -0.17; TCGA BRCA -0.126; TCGA CESC -0.344; TCGA COAD -0.381; TCGA ESCA -0.294; TCGA HNSC -0.28; TCGA LIHC -0.165; TCGA LUAD -0.173; TCGA LUSC -0.51; TCGA PAAD -0.186; TCGA THCA -0.079; TCGA STAD -0.155 |
hsa-miR-222-3p | JMY | 10 cancers: BLCA; COAD; ESCA; HNSC; LGG; LIHC; LUAD; PAAD; SARC; STAD | MirTarget | TCGA BLCA -0.229; TCGA COAD -0.172; TCGA ESCA -0.332; TCGA HNSC -0.094; TCGA LGG -0.072; TCGA LIHC -0.085; TCGA LUAD -0.11; TCGA PAAD -0.145; TCGA SARC -0.162; TCGA STAD -0.337 |
hsa-miR-222-3p | MEX3A | 10 cancers: BLCA; CESC; COAD; HNSC; KIRP; LGG; LUAD; OV; PRAD; SARC | MirTarget | TCGA BLCA -0.296; TCGA CESC -0.514; TCGA COAD -0.319; TCGA HNSC -0.297; TCGA KIRP -0.412; TCGA LGG -0.398; TCGA LUAD -0.419; TCGA OV -0.414; TCGA PRAD -0.496; TCGA SARC -0.293 |
hsa-miR-222-3p | ZNF615 | 11 cancers: BLCA; BRCA; COAD; HNSC; KIRC; LUAD; OV; PRAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.29; TCGA BRCA -0.092; TCGA COAD -0.151; TCGA HNSC -0.162; TCGA KIRC -0.091; TCGA LUAD -0.084; TCGA OV -0.145; TCGA PRAD -0.169; TCGA SARC -0.12; TCGA STAD -0.362; TCGA UCEC -0.065 |
hsa-miR-222-3p | SNX4 | 10 cancers: BLCA; CESC; HNSC; KIRC; KIRP; LIHC; LUAD; OV; PRAD; THCA | MirTarget | TCGA BLCA -0.114; TCGA CESC -0.125; TCGA HNSC -0.075; TCGA KIRC -0.186; TCGA KIRP -0.149; TCGA LIHC -0.149; TCGA LUAD -0.12; TCGA OV -0.118; TCGA PRAD -0.196; TCGA THCA -0.22 |
hsa-miR-222-3p | CCDC126 | 10 cancers: BLCA; BRCA; HNSC; LIHC; LUAD; OV; PAAD; PRAD; THCA; UCEC | MirTarget | TCGA BLCA -0.111; TCGA BRCA -0.141; TCGA HNSC -0.133; TCGA LIHC -0.115; TCGA LUAD -0.085; TCGA OV -0.089; TCGA PAAD -0.144; TCGA PRAD -0.148; TCGA THCA -0.19; TCGA UCEC -0.118 |
hsa-miR-222-3p | TUB | 13 cancers: BLCA; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LUSC; OV; PAAD; SARC; THCA; STAD | MirTarget | TCGA BLCA -0.216; TCGA COAD -0.733; TCGA ESCA -0.767; TCGA HNSC -0.759; TCGA KIRC -0.517; TCGA KIRP -0.353; TCGA LGG -0.167; TCGA LUSC -0.307; TCGA OV -0.17; TCGA PAAD -0.286; TCGA SARC -0.584; TCGA THCA -0.336; TCGA STAD -0.786 |
hsa-miR-222-3p | WDR35 | 12 cancers: BLCA; CESC; HNSC; KIRC; KIRP; LGG; LUAD; LUSC; OV; PAAD; SARC; STAD | MirTarget | TCGA BLCA -0.078; TCGA CESC -0.253; TCGA HNSC -0.19; TCGA KIRC -0.158; TCGA KIRP -0.134; TCGA LGG -0.054; TCGA LUAD -0.135; TCGA LUSC -0.203; TCGA OV -0.232; TCGA PAAD -0.166; TCGA SARC -0.103; TCGA STAD -0.321 |
hsa-miR-222-3p | HIPK1 | 12 cancers: BLCA; CESC; COAD; ESCA; HNSC; LIHC; LUSC; OV; SARC; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.053; TCGA CESC -0.175; TCGA COAD -0.114; TCGA ESCA -0.153; TCGA HNSC -0.127; TCGA LIHC -0.079; TCGA LUSC -0.132; TCGA OV -0.064; TCGA SARC -0.071; TCGA THCA -0.095; TCGA STAD -0.102; TCGA UCEC -0.092 |
hsa-miR-222-3p | NAP1L5 | 10 cancers: BLCA; CESC; COAD; ESCA; HNSC; LIHC; PAAD; SARC; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.21; TCGA CESC -0.136; TCGA COAD -0.153; TCGA ESCA -0.236; TCGA HNSC -0.209; TCGA LIHC -0.304; TCGA PAAD -0.404; TCGA SARC -0.335; TCGA THCA -0.135; TCGA STAD -0.581 |
hsa-miR-222-3p | NBPF3 | 11 cancers: BLCA; BRCA; CESC; COAD; HNSC; KIRC; KIRP; OV; PRAD; THCA; STAD | MirTarget | TCGA BLCA -0.183; TCGA BRCA -0.094; TCGA CESC -0.247; TCGA COAD -0.228; TCGA HNSC -0.179; TCGA KIRC -0.147; TCGA KIRP -0.268; TCGA OV -0.1; TCGA PRAD -0.079; TCGA THCA -0.127; TCGA STAD -0.122 |
hsa-miR-222-3p | ADAM22 | 11 cancers: BLCA; BRCA; CESC; COAD; HNSC; LGG; LUSC; OV; SARC; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.395; TCGA BRCA -0.181; TCGA CESC -0.73; TCGA COAD -0.404; TCGA HNSC -0.662; TCGA LGG -0.086; TCGA LUSC -0.653; TCGA OV -0.335; TCGA SARC -0.46; TCGA THCA -0.718; TCGA STAD -0.305 |
hsa-miR-222-3p | DPY19L3 | 12 cancers: BLCA; BRCA; CESC; COAD; HNSC; LUAD; LUSC; OV; PRAD; SARC; THCA; STAD | MirTarget | TCGA BLCA -0.253; TCGA BRCA -0.097; TCGA CESC -0.389; TCGA COAD -0.169; TCGA HNSC -0.277; TCGA LUAD -0.168; TCGA LUSC -0.224; TCGA OV -0.172; TCGA PRAD -0.214; TCGA SARC -0.132; TCGA THCA -0.173; TCGA STAD -0.087 |
hsa-miR-222-3p | MIA3 | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; OV; PRAD; SARC; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.075; TCGA BRCA -0.092; TCGA CESC -0.158; TCGA COAD -0.156; TCGA ESCA -0.08; TCGA HNSC -0.102; TCGA LIHC -0.131; TCGA LUAD -0.177; TCGA OV -0.076; TCGA PRAD -0.286; TCGA SARC -0.068; TCGA THCA -0.14; TCGA STAD -0.067; TCGA UCEC -0.118 |
hsa-miR-222-3p | NRK | 10 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LUSC; PAAD; SARC; STAD | MirTarget; miRNATAP | TCGA BLCA -0.34; TCGA BRCA -0.217; TCGA CESC -0.316; TCGA COAD -1.066; TCGA ESCA -1.074; TCGA HNSC -0.983; TCGA LUSC -0.589; TCGA PAAD -0.441; TCGA SARC -0.726; TCGA STAD -1.017 |
hsa-miR-222-3p | NFATC3 | 9 cancers: BLCA; COAD; HNSC; LIHC; LUAD; LUSC; OV; THCA; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.11; TCGA COAD -0.08; TCGA HNSC -0.075; TCGA LIHC -0.133; TCGA LUAD -0.088; TCGA LUSC -0.186; TCGA OV -0.12; TCGA THCA -0.141; TCGA UCEC -0.06 |
hsa-miR-222-3p | MIER3 | 10 cancers: BLCA; BRCA; CESC; HNSC; LGG; LIHC; LUAD; LUSC; SARC; THCA | MirTarget; miRNATAP | TCGA BLCA -0.096; TCGA BRCA -0.09; TCGA CESC -0.161; TCGA HNSC -0.075; TCGA LGG -0.093; TCGA LIHC -0.095; TCGA LUAD -0.094; TCGA LUSC -0.11; TCGA SARC -0.141; TCGA THCA -0.055 |
hsa-miR-222-3p | ASPA | 12 cancers: BLCA; CESC; COAD; ESCA; KIRC; KIRP; LIHC; LUSC; PAAD; SARC; THCA; STAD | MirTarget | TCGA BLCA -0.458; TCGA CESC -0.268; TCGA COAD -0.713; TCGA ESCA -0.769; TCGA KIRC -0.762; TCGA KIRP -0.491; TCGA LIHC -0.558; TCGA LUSC -0.68; TCGA PAAD -0.623; TCGA SARC -0.239; TCGA THCA -0.412; TCGA STAD -0.705 |
hsa-miR-222-3p | GDF9 | 9 cancers: BLCA; BRCA; CESC; KIRP; LGG; LIHC; PRAD; SARC; THCA | MirTarget | TCGA BLCA -0.295; TCGA BRCA -0.3; TCGA CESC -0.107; TCGA KIRP -0.213; TCGA LGG -0.156; TCGA LIHC -0.092; TCGA PRAD -0.203; TCGA SARC -0.193; TCGA THCA -0.245 |
hsa-miR-222-3p | MGAT4A | 10 cancers: BLCA; BRCA; CESC; HNSC; KIRC; KIRP; LUAD; LUSC; PAAD; PRAD | MirTarget | TCGA BLCA -0.32; TCGA BRCA -0.119; TCGA CESC -0.33; TCGA HNSC -0.326; TCGA KIRC -0.183; TCGA KIRP -0.125; TCGA LUAD -0.147; TCGA LUSC -0.536; TCGA PAAD -0.26; TCGA PRAD -0.153 |
hsa-miR-222-3p | SENP7 | 13 cancers: BLCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LUAD; LUSC; PRAD; SARC; STAD | MirTarget | TCGA BLCA -0.205; TCGA CESC -0.075; TCGA COAD -0.116; TCGA ESCA -0.232; TCGA HNSC -0.103; TCGA KIRC -0.104; TCGA KIRP -0.117; TCGA LGG -0.121; TCGA LUAD -0.052; TCGA LUSC -0.115; TCGA PRAD -0.069; TCGA SARC -0.18; TCGA STAD -0.319 |
hsa-miR-222-3p | PPP1R12B | 10 cancers: BLCA; COAD; ESCA; HNSC; LIHC; LUSC; PAAD; SARC; THCA; STAD | mirMAP | TCGA BLCA -0.262; TCGA COAD -0.613; TCGA ESCA -0.625; TCGA HNSC -0.364; TCGA LIHC -0.094; TCGA LUSC -0.181; TCGA PAAD -0.203; TCGA SARC -0.477; TCGA THCA -0.162; TCGA STAD -0.942 |
hsa-miR-222-3p | SEMA5A | 10 cancers: BLCA; COAD; HNSC; KIRC; KIRP; LGG; LIHC; LUSC; PAAD; SARC | mirMAP | TCGA BLCA -0.717; TCGA COAD -0.367; TCGA HNSC -0.342; TCGA KIRC -0.231; TCGA KIRP -0.444; TCGA LGG -0.076; TCGA LIHC -0.283; TCGA LUSC -0.51; TCGA PAAD -0.229; TCGA SARC -0.302 |
hsa-miR-222-3p | FNBP1L | 10 cancers: BLCA; CESC; HNSC; KIRC; KIRP; LUAD; OV; PRAD; SARC; UCEC | mirMAP | TCGA BLCA -0.219; TCGA CESC -0.283; TCGA HNSC -0.159; TCGA KIRC -0.132; TCGA KIRP -0.147; TCGA LUAD -0.151; TCGA OV -0.139; TCGA PRAD -0.238; TCGA SARC -0.153; TCGA UCEC -0.07 |
hsa-miR-222-3p | PPM1L | 10 cancers: BLCA; CESC; COAD; ESCA; HNSC; LIHC; SARC; THCA; STAD; UCEC | mirMAP | TCGA BLCA -0.546; TCGA CESC -0.349; TCGA COAD -0.206; TCGA ESCA -0.297; TCGA HNSC -0.664; TCGA LIHC -0.281; TCGA SARC -0.252; TCGA THCA -0.484; TCGA STAD -0.32; TCGA UCEC -0.238 |
hsa-miR-222-3p | JAM3 | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; LUAD; LUSC; PAAD; SARC; THCA; STAD | mirMAP | TCGA BLCA -0.246; TCGA BRCA -0.069; TCGA CESC -0.215; TCGA COAD -0.54; TCGA ESCA -0.494; TCGA HNSC -0.432; TCGA KIRC -0.126; TCGA LUAD -0.188; TCGA LUSC -0.582; TCGA PAAD -0.196; TCGA SARC -0.194; TCGA THCA -0.117; TCGA STAD -0.655 |
hsa-miR-222-3p | PRTG | 11 cancers: BLCA; BRCA; CESC; COAD; HNSC; LGG; LUAD; LUSC; OV; THCA; STAD | mirMAP | TCGA BLCA -0.162; TCGA BRCA -0.153; TCGA CESC -0.611; TCGA COAD -0.754; TCGA HNSC -0.43; TCGA LGG -0.291; TCGA LUAD -0.19; TCGA LUSC -0.957; TCGA OV -0.219; TCGA THCA -0.446; TCGA STAD -0.59 |
hsa-miR-222-3p | FIGN | 9 cancers: BLCA; CESC; COAD; ESCA; HNSC; KIRC; LUSC; PAAD; STAD | mirMAP | TCGA BLCA -0.255; TCGA CESC -0.363; TCGA COAD -0.897; TCGA ESCA -0.606; TCGA HNSC -0.296; TCGA KIRC -0.144; TCGA LUSC -0.434; TCGA PAAD -0.268; TCGA STAD -0.619 |
hsa-miR-222-3p | ZNF677 | 12 cancers: BLCA; CESC; COAD; ESCA; HNSC; LGG; LUSC; PAAD; PRAD; SARC; THCA; STAD | mirMAP | TCGA BLCA -0.341; TCGA CESC -0.252; TCGA COAD -0.627; TCGA ESCA -0.565; TCGA HNSC -0.589; TCGA LGG -0.099; TCGA LUSC -0.471; TCGA PAAD -0.333; TCGA PRAD -0.152; TCGA SARC -0.216; TCGA THCA -0.077; TCGA STAD -0.645 |
hsa-miR-222-3p | SAMD5 | 10 cancers: BLCA; CESC; HNSC; KIRC; LIHC; LUAD; LUSC; PAAD; PRAD; THCA | mirMAP | TCGA BLCA -0.208; TCGA CESC -0.313; TCGA HNSC -0.686; TCGA KIRC -0.235; TCGA LIHC -0.41; TCGA LUAD -0.242; TCGA LUSC -0.441; TCGA PAAD -0.359; TCGA PRAD -0.56; TCGA THCA -0.483 |
hsa-miR-222-3p | HECTD2 | 11 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LUAD; LUSC; PAAD; SARC; STAD | miRNATAP | TCGA BLCA -0.072; TCGA BRCA -0.131; TCGA CESC -0.145; TCGA COAD -0.329; TCGA ESCA -0.241; TCGA HNSC -0.088; TCGA LUAD -0.14; TCGA LUSC -0.138; TCGA PAAD -0.223; TCGA SARC -0.172; TCGA STAD -0.43 |
hsa-miR-222-3p | ZNF704 | 14 cancers: BLCA; BRCA; CESC; COAD; HNSC; KIRC; LGG; LUAD; LUSC; PAAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.367; TCGA BRCA -0.09; TCGA CESC -0.478; TCGA COAD -0.425; TCGA HNSC -0.52; TCGA KIRC -0.334; TCGA LGG -0.14; TCGA LUAD -0.207; TCGA LUSC -0.434; TCGA PAAD -0.218; TCGA SARC -0.388; TCGA THCA -0.192; TCGA STAD -0.406; TCGA UCEC -0.245 |
hsa-miR-222-3p | DGKE | 11 cancers: BLCA; CESC; HNSC; KIRC; LIHC; LUAD; PAAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.223; TCGA CESC -0.154; TCGA HNSC -0.093; TCGA KIRC -0.188; TCGA LIHC -0.238; TCGA LUAD -0.083; TCGA PAAD -0.153; TCGA SARC -0.092; TCGA THCA -0.054; TCGA STAD -0.214; TCGA UCEC -0.149 |
hsa-miR-222-3p | UBN2 | 11 cancers: BLCA; BRCA; CESC; HNSC; KIRP; LGG; LUAD; PRAD; SARC; THCA; UCEC | miRNATAP | TCGA BLCA -0.19; TCGA BRCA -0.052; TCGA CESC -0.145; TCGA HNSC -0.126; TCGA KIRP -0.236; TCGA LGG -0.123; TCGA LUAD -0.119; TCGA PRAD -0.143; TCGA SARC -0.108; TCGA THCA -0.125; TCGA UCEC -0.11 |
hsa-miR-222-3p | SEC62 | 9 cancers: BLCA; CESC; COAD; HNSC; LIHC; PAAD; PRAD; THCA; STAD | miRNATAP | TCGA BLCA -0.064; TCGA CESC -0.093; TCGA COAD -0.076; TCGA HNSC -0.076; TCGA LIHC -0.178; TCGA PAAD -0.06; TCGA PRAD -0.058; TCGA THCA -0.12; TCGA STAD -0.121 |
hsa-miR-222-3p | NOVA1 | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; LUSC; OV; PAAD; SARC; STAD | miRNATAP | TCGA BLCA -0.524; TCGA BRCA -0.386; TCGA CESC -0.457; TCGA COAD -0.867; TCGA ESCA -0.905; TCGA HNSC -0.822; TCGA LGG -0.152; TCGA LUSC -0.403; TCGA OV -0.442; TCGA PAAD -0.671; TCGA SARC -0.217; TCGA STAD -0.997 |
hsa-miR-222-3p | AXIN2 | 11 cancers: BLCA; BRCA; CESC; HNSC; KIRP; LGG; LUAD; LUSC; PAAD; SARC; THCA | miRNATAP | TCGA BLCA -0.32; TCGA BRCA -0.187; TCGA CESC -0.535; TCGA HNSC -0.453; TCGA KIRP -0.28; TCGA LGG -0.057; TCGA LUAD -0.248; TCGA LUSC -0.541; TCGA PAAD -0.133; TCGA SARC -0.241; TCGA THCA -0.23 |
hsa-miR-222-3p | SLC4A4 | 10 cancers: BLCA; CESC; HNSC; KIRC; LIHC; LUSC; PAAD; PRAD; SARC; THCA | miRNATAP | TCGA BLCA -0.365; TCGA CESC -1.042; TCGA HNSC -0.894; TCGA KIRC -0.453; TCGA LIHC -0.738; TCGA LUSC -0.536; TCGA PAAD -0.594; TCGA PRAD -0.165; TCGA SARC -0.192; TCGA THCA -1.005 |
hsa-miR-222-3p | CACNB4 | 11 cancers: BLCA; CESC; COAD; ESCA; HNSC; LUAD; OV; PAAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.451; TCGA CESC -0.401; TCGA COAD -0.548; TCGA ESCA -0.291; TCGA HNSC -0.726; TCGA LUAD -0.21; TCGA OV -0.255; TCGA PAAD -0.325; TCGA SARC -0.243; TCGA THCA -0.465; TCGA STAD -0.481 |
hsa-miR-222-3p | ERBB4 | 10 cancers: BLCA; BRCA; CESC; ESCA; HNSC; LUSC; PAAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.82; TCGA BRCA -0.96; TCGA CESC -1.212; TCGA ESCA -0.45; TCGA HNSC -1.205; TCGA LUSC -0.931; TCGA PAAD -0.689; TCGA SARC -0.414; TCGA THCA -0.212; TCGA STAD -0.594 |
hsa-miR-222-3p | SEMA6D | 10 cancers: BLCA; ESCA; HNSC; LIHC; LUAD; LUSC; PAAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.312; TCGA ESCA -0.496; TCGA HNSC -0.683; TCGA LIHC -0.206; TCGA LUAD -0.177; TCGA LUSC -0.331; TCGA PAAD -0.486; TCGA SARC -0.425; TCGA THCA -0.367; TCGA STAD -0.483 |
hsa-miR-222-3p | C3orf70 | 11 cancers: BLCA; COAD; ESCA; HNSC; KIRC; LUAD; LUSC; PAAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.516; TCGA COAD -0.414; TCGA ESCA -0.346; TCGA HNSC -0.399; TCGA KIRC -0.164; TCGA LUAD -0.334; TCGA LUSC -0.565; TCGA PAAD -0.352; TCGA SARC -0.423; TCGA THCA -0.109; TCGA STAD -0.867 |
hsa-miR-222-3p | RUNX1T1 | 11 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; LUSC; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.332; TCGA BRCA -0.137; TCGA CESC -0.469; TCGA COAD -1.032; TCGA ESCA -0.744; TCGA HNSC -0.762; TCGA KIRC -0.18; TCGA LUSC -0.981; TCGA SARC -0.224; TCGA THCA -0.386; TCGA STAD -0.708 |
hsa-miR-222-3p | WNK3 | 12 cancers: BLCA; ESCA; HNSC; LGG; LIHC; LUAD; OV; PAAD; PRAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.196; TCGA ESCA -0.338; TCGA HNSC -0.451; TCGA LGG -0.117; TCGA LIHC -0.431; TCGA LUAD -0.26; TCGA OV -0.143; TCGA PAAD -0.465; TCGA PRAD -0.308; TCGA SARC -0.276; TCGA THCA -0.172; TCGA STAD -0.62 |
hsa-miR-222-3p | PDZRN4 | 10 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LUSC; PAAD; SARC; STAD | miRNATAP | TCGA BLCA -0.413; TCGA BRCA -0.141; TCGA CESC -0.316; TCGA COAD -1.26; TCGA ESCA -1.413; TCGA HNSC -0.932; TCGA LUSC -0.845; TCGA PAAD -0.508; TCGA SARC -0.656; TCGA STAD -1.481 |
hsa-miR-222-3p | MAPK10 | 12 cancers: BLCA; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; OV; PAAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.438; TCGA COAD -0.881; TCGA ESCA -0.56; TCGA HNSC -0.277; TCGA KIRC -0.3; TCGA KIRP -0.312; TCGA LIHC -0.215; TCGA OV -0.373; TCGA PAAD -0.494; TCGA SARC -0.722; TCGA THCA -0.172; TCGA STAD -0.839 |
hsa-miR-222-3p | SBK1 | 11 cancers: BLCA; BRCA; CESC; HNSC; KIRP; LGG; LUAD; OV; PRAD; SARC; THCA | miRNATAP | TCGA BLCA -0.563; TCGA BRCA -0.244; TCGA CESC -0.687; TCGA HNSC -0.657; TCGA KIRP -0.519; TCGA LGG -0.201; TCGA LUAD -0.47; TCGA OV -0.295; TCGA PRAD -0.4; TCGA SARC -0.384; TCGA THCA -0.09 |
hsa-miR-222-3p | SHANK2 | 13 cancers: BLCA; BRCA; CESC; HNSC; KIRC; KIRP; LGG; LUAD; LUSC; PRAD; SARC; THCA; UCEC | miRNATAP | TCGA BLCA -0.211; TCGA BRCA -0.143; TCGA CESC -0.684; TCGA HNSC -0.395; TCGA KIRC -0.23; TCGA KIRP -0.207; TCGA LGG -0.13; TCGA LUAD -0.113; TCGA LUSC -0.363; TCGA PRAD -0.193; TCGA SARC -0.584; TCGA THCA -0.463; TCGA UCEC -0.167 |
hsa-miR-222-3p | BTBD3 | 9 cancers: BLCA; CESC; HNSC; LUAD; LUSC; OV; PAAD; SARC; STAD | miRNATAP | TCGA BLCA -0.113; TCGA CESC -0.266; TCGA HNSC -0.076; TCGA LUAD -0.132; TCGA LUSC -0.101; TCGA OV -0.18; TCGA PAAD -0.122; TCGA SARC -0.121; TCGA STAD -0.106 |
hsa-miR-222-3p | RALGAPA1 | 18 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; OV; PAAD; PRAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.144; TCGA BRCA -0.15; TCGA CESC -0.142; TCGA COAD -0.13; TCGA ESCA -0.163; TCGA HNSC -0.076; TCGA KIRC -0.125; TCGA KIRP -0.066; TCGA LGG -0.069; TCGA LIHC -0.057; TCGA LUAD -0.212; TCGA OV -0.065; TCGA PAAD -0.105; TCGA PRAD -0.192; TCGA SARC -0.206; TCGA THCA -0.113; TCGA STAD -0.156; TCGA UCEC -0.143 |
hsa-miR-222-3p | ZFHX3 | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LUAD; LUSC; OV; SARC; STAD; UCEC | miRNATAP | TCGA BLCA -0.373; TCGA BRCA -0.099; TCGA CESC -0.278; TCGA COAD -0.274; TCGA ESCA -0.112; TCGA HNSC -0.122; TCGA LUAD -0.224; TCGA LUSC -0.199; TCGA OV -0.088; TCGA SARC -0.193; TCGA STAD -0.281; TCGA UCEC -0.226 |
hsa-miR-222-3p | NTF3 | 11 cancers: BLCA; COAD; ESCA; HNSC; KIRC; LIHC; LUAD; LUSC; OV; SARC; STAD | miRNATAP | TCGA BLCA -0.529; TCGA COAD -0.523; TCGA ESCA -0.288; TCGA HNSC -0.598; TCGA KIRC -0.286; TCGA LIHC -0.45; TCGA LUAD -0.159; TCGA LUSC -0.298; TCGA OV -0.283; TCGA SARC -0.591; TCGA STAD -0.403 |
hsa-miR-222-3p | CASZ1 | 12 cancers: BLCA; BRCA; HNSC; KIRP; LGG; LUAD; LUSC; PRAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.237; TCGA BRCA -0.276; TCGA HNSC -0.122; TCGA KIRP -0.254; TCGA LGG -0.15; TCGA LUAD -0.121; TCGA LUSC -0.123; TCGA PRAD -0.15; TCGA SARC -0.36; TCGA THCA -0.209; TCGA STAD -0.17; TCGA UCEC -0.13 |
hsa-miR-222-3p | RND2 | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRP; LGG; OV; PAAD; THCA; STAD | miRNATAP | TCGA BLCA -0.197; TCGA BRCA -0.112; TCGA CESC -0.232; TCGA COAD -0.501; TCGA ESCA -0.471; TCGA HNSC -0.588; TCGA KIRP -0.254; TCGA LGG -0.309; TCGA OV -0.4; TCGA PAAD -0.491; TCGA THCA -0.071; TCGA STAD -0.754 |
hsa-miR-222-3p | BMF | 11 cancers: BLCA; BRCA; CESC; COAD; HNSC; LGG; LUAD; LUSC; OV; PRAD; SARC | miRNATAP | TCGA BLCA -0.244; TCGA BRCA -0.124; TCGA CESC -0.393; TCGA COAD -0.335; TCGA HNSC -0.166; TCGA LGG -0.268; TCGA LUAD -0.105; TCGA LUSC -0.475; TCGA OV -0.322; TCGA PRAD -0.163; TCGA SARC -0.214 |
hsa-miR-222-3p | FAM13A | 11 cancers: BLCA; CESC; ESCA; HNSC; KIRC; KIRP; LIHC; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.208; TCGA CESC -0.393; TCGA ESCA -0.254; TCGA HNSC -0.315; TCGA KIRC -0.151; TCGA KIRP -0.129; TCGA LIHC -0.572; TCGA SARC -0.147; TCGA THCA -0.182; TCGA STAD -0.225; TCGA UCEC -0.131 |
hsa-miR-222-3p | PPP1R15B | 11 cancers: BLCA; CESC; HNSC; KIRC; LIHC; LUAD; LUSC; OV; PRAD; SARC; THCA | miRNATAP | TCGA BLCA -0.074; TCGA CESC -0.056; TCGA HNSC -0.053; TCGA KIRC -0.171; TCGA LIHC -0.093; TCGA LUAD -0.117; TCGA LUSC -0.101; TCGA OV -0.101; TCGA PRAD -0.097; TCGA SARC -0.101; TCGA THCA -0.124 |
hsa-miR-222-3p | PPARGC1A | 11 cancers: BLCA; CESC; HNSC; KIRP; LIHC; LUAD; LUSC; PAAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.276; TCGA CESC -0.693; TCGA HNSC -0.989; TCGA KIRP -0.216; TCGA LIHC -0.781; TCGA LUAD -0.78; TCGA LUSC -0.761; TCGA PAAD -0.456; TCGA SARC -0.473; TCGA THCA -0.777; TCGA STAD -0.387 |
hsa-miR-222-3p | ESR1 | 10 cancers: BRCA; CESC; COAD; HNSC; KIRC; LIHC; LUSC; PAAD; STAD; UCEC | miRNAWalker2 validate; miRNATAP | TCGA BRCA -0.83; TCGA CESC -0.357; TCGA COAD -0.654; TCGA HNSC -0.226; TCGA KIRC -0.189; TCGA LIHC -1.114; TCGA LUSC -0.43; TCGA PAAD -0.352; TCGA STAD -0.394; TCGA UCEC -0.373 |
hsa-miR-222-3p | SHISA2 | 10 cancers: BRCA; CESC; COAD; HNSC; LUAD; LUSC; PRAD; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BRCA -0.212; TCGA CESC -0.347; TCGA COAD -0.745; TCGA HNSC -0.376; TCGA LUAD -0.279; TCGA LUSC -0.556; TCGA PRAD -0.505; TCGA SARC -0.619; TCGA THCA -0.075; TCGA STAD -0.181 |
hsa-miR-222-3p | GAB1 | 12 cancers: BRCA; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUSC; OV; SARC; STAD | MirTarget; miRNATAP | TCGA BRCA -0.081; TCGA COAD -0.146; TCGA ESCA -0.296; TCGA HNSC -0.077; TCGA KIRC -0.157; TCGA KIRP -0.133; TCGA LGG -0.12; TCGA LIHC -0.114; TCGA LUSC -0.132; TCGA OV -0.118; TCGA SARC -0.22; TCGA STAD -0.364 |
hsa-miR-222-3p | ZADH2 | 11 cancers: BRCA; ESCA; HNSC; KIRC; LIHC; OV; PAAD; PRAD; SARC; THCA; STAD | MirTarget | TCGA BRCA -0.082; TCGA ESCA -0.139; TCGA HNSC -0.08; TCGA KIRC -0.112; TCGA LIHC -0.176; TCGA OV -0.081; TCGA PAAD -0.155; TCGA PRAD -0.057; TCGA SARC -0.097; TCGA THCA -0.131; TCGA STAD -0.073 |
hsa-miR-222-3p | HOOK1 | 9 cancers: BRCA; CESC; KIRC; KIRP; LIHC; LUAD; PAAD; PRAD; SARC | MirTarget | TCGA BRCA -0.117; TCGA CESC -0.121; TCGA KIRC -0.387; TCGA KIRP -0.143; TCGA LIHC -0.15; TCGA LUAD -0.328; TCGA PAAD -0.137; TCGA PRAD -0.264; TCGA SARC -0.39 |
hsa-miR-222-3p | FAM35A | 14 cancers: BRCA; CESC; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; OV; PRAD; SARC; THCA; UCEC | MirTarget | TCGA BRCA -0.07; TCGA CESC -0.134; TCGA HNSC -0.065; TCGA KIRC -0.191; TCGA KIRP -0.226; TCGA LGG -0.16; TCGA LIHC -0.063; TCGA LUAD -0.091; TCGA LUSC -0.134; TCGA OV -0.074; TCGA PRAD -0.11; TCGA SARC -0.094; TCGA THCA -0.171; TCGA UCEC -0.081 |
hsa-miR-222-3p | ZHX3 | 9 cancers: BRCA; CESC; ESCA; KIRC; LIHC; PAAD; PRAD; THCA; STAD | mirMAP | TCGA BRCA -0.072; TCGA CESC -0.089; TCGA ESCA -0.323; TCGA KIRC -0.12; TCGA LIHC -0.264; TCGA PAAD -0.266; TCGA PRAD -0.129; TCGA THCA -0.199; TCGA STAD -0.328 |
hsa-miR-222-3p | GPM6A | 12 cancers: BRCA; COAD; ESCA; HNSC; KIRC; LGG; LIHC; LUSC; PAAD; SARC; THCA; STAD | miRNATAP | TCGA BRCA -0.171; TCGA COAD -1.66; TCGA ESCA -1.194; TCGA HNSC -0.336; TCGA KIRC -0.319; TCGA LGG -0.074; TCGA LIHC -0.74; TCGA LUSC -1.139; TCGA PAAD -0.758; TCGA SARC -0.399; TCGA THCA -0.69; TCGA STAD -1.261 |
hsa-miR-222-3p | ATXN1 | 10 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LUSC; SARC; STAD | miRNATAP | TCGA BRCA -0.09; TCGA CESC -0.108; TCGA COAD -0.235; TCGA ESCA -0.15; TCGA HNSC -0.177; TCGA KIRC -0.095; TCGA KIRP -0.087; TCGA LUSC -0.104; TCGA SARC -0.085; TCGA STAD -0.245 |
hsa-miR-222-3p | EPB41L2 | 9 cancers: CESC; HNSC; KIRP; LUSC; OV; PAAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA CESC -0.156; TCGA HNSC -0.224; TCGA KIRP -0.102; TCGA LUSC -0.274; TCGA OV -0.115; TCGA PAAD -0.232; TCGA THCA -0.104; TCGA STAD -0.171; TCGA UCEC -0.137 |
hsa-miR-222-3p | FAM53C | 9 cancers: CESC; ESCA; HNSC; LUAD; LUSC; PAAD; PRAD; SARC; STAD | miRNAWalker2 validate | TCGA CESC -0.077; TCGA ESCA -0.079; TCGA HNSC -0.065; TCGA LUAD -0.072; TCGA LUSC -0.068; TCGA PAAD -0.059; TCGA PRAD -0.084; TCGA SARC -0.133; TCGA STAD -0.101 |
hsa-miR-222-3p | FOXO3 | 9 cancers: CESC; HNSC; KIRC; LUSC; PAAD; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate; miRTarBase | TCGA CESC -0.07; TCGA HNSC -0.109; TCGA KIRC -0.097; TCGA LUSC -0.097; TCGA PAAD -0.124; TCGA PRAD -0.081; TCGA SARC -0.115; TCGA STAD -0.087; TCGA UCEC -0.059 |
hsa-miR-222-3p | HIPK2 | 10 cancers: CESC; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; PRAD | miRNAWalker2 validate; miRNATAP | TCGA CESC -0.228; TCGA HNSC -0.264; TCGA KIRC -0.301; TCGA KIRP -0.21; TCGA LGG -0.123; TCGA LIHC -0.208; TCGA LUAD -0.135; TCGA LUSC -0.247; TCGA PAAD -0.251; TCGA PRAD -0.291 |
hsa-miR-222-3p | SV2A | 10 cancers: CESC; COAD; ESCA; HNSC; LUAD; LUSC; OV; PAAD; SARC; STAD | miRNAWalker2 validate | TCGA CESC -0.271; TCGA COAD -0.486; TCGA ESCA -0.422; TCGA HNSC -0.463; TCGA LUAD -0.28; TCGA LUSC -0.202; TCGA OV -0.202; TCGA PAAD -0.341; TCGA SARC -0.294; TCGA STAD -0.524 |
hsa-miR-222-3p | DIRAS3 | 11 cancers: CESC; COAD; ESCA; HNSC; KIRP; LIHC; LUSC; OV; PAAD; SARC; STAD | miRTarBase | TCGA CESC -0.307; TCGA COAD -0.22; TCGA ESCA -0.224; TCGA HNSC -0.448; TCGA KIRP -0.392; TCGA LIHC -0.84; TCGA LUSC -0.584; TCGA OV -0.169; TCGA PAAD -0.519; TCGA SARC -0.29; TCGA STAD -0.662 |
hsa-miR-222-3p | TOX | 9 cancers: CESC; COAD; ESCA; LGG; LUSC; OV; PAAD; THCA; STAD | MirTarget; miRNATAP | TCGA CESC -0.144; TCGA COAD -0.538; TCGA ESCA -0.388; TCGA LGG -0.266; TCGA LUSC -0.702; TCGA OV -0.194; TCGA PAAD -0.393; TCGA THCA -0.265; TCGA STAD -0.652 |
hsa-miR-222-3p | CXCL12 | 10 cancers: CESC; COAD; ESCA; HNSC; KIRC; LIHC; LUSC; PAAD; THCA; STAD | MirTarget | TCGA CESC -0.26; TCGA COAD -0.656; TCGA ESCA -0.653; TCGA HNSC -0.749; TCGA KIRC -0.241; TCGA LIHC -0.247; TCGA LUSC -0.798; TCGA PAAD -0.663; TCGA THCA -0.162; TCGA STAD -0.6 |
hsa-miR-222-3p | FERMT2 | 10 cancers: CESC; COAD; ESCA; HNSC; LIHC; LUAD; LUSC; PAAD; SARC; STAD | MirTarget; miRNATAP | TCGA CESC -0.53; TCGA COAD -0.786; TCGA ESCA -0.641; TCGA HNSC -0.455; TCGA LIHC -0.187; TCGA LUAD -0.073; TCGA LUSC -0.596; TCGA PAAD -0.196; TCGA SARC -0.151; TCGA STAD -0.76 |
hsa-miR-222-3p | ATF2 | 11 cancers: CESC; COAD; HNSC; KIRC; LUAD; LUSC; OV; PRAD; SARC; THCA; STAD | MirTarget | TCGA CESC -0.17; TCGA COAD -0.148; TCGA HNSC -0.176; TCGA KIRC -0.093; TCGA LUAD -0.132; TCGA LUSC -0.063; TCGA OV -0.082; TCGA PRAD -0.086; TCGA SARC -0.097; TCGA THCA -0.162; TCGA STAD -0.074 |
hsa-miR-222-3p | KCNK2 | 9 cancers: CESC; COAD; ESCA; HNSC; KIRP; LIHC; PAAD; THCA; STAD | MirTarget | TCGA CESC -0.335; TCGA COAD -0.818; TCGA ESCA -1.079; TCGA HNSC -0.777; TCGA KIRP -0.606; TCGA LIHC -0.219; TCGA PAAD -0.648; TCGA THCA -0.639; TCGA STAD -0.876 |
hsa-miR-222-3p | HIPK3 | 9 cancers: CESC; COAD; ESCA; HNSC; LIHC; LUSC; SARC; THCA; STAD | MirTarget | TCGA CESC -0.231; TCGA COAD -0.332; TCGA ESCA -0.305; TCGA HNSC -0.298; TCGA LIHC -0.229; TCGA LUSC -0.141; TCGA SARC -0.204; TCGA THCA -0.136; TCGA STAD -0.326 |
hsa-miR-222-3p | FAM168A | 10 cancers: CESC; COAD; ESCA; HNSC; LUSC; OV; PRAD; SARC; THCA; STAD | mirMAP | TCGA CESC -0.151; TCGA COAD -0.3; TCGA ESCA -0.195; TCGA HNSC -0.123; TCGA LUSC -0.117; TCGA OV -0.066; TCGA PRAD -0.134; TCGA SARC -0.107; TCGA THCA -0.083; TCGA STAD -0.19 |
hsa-miR-222-3p | TCF4 | 10 cancers: CESC; COAD; ESCA; HNSC; LGG; LUSC; PAAD; SARC; THCA; STAD | miRNATAP | TCGA CESC -0.151; TCGA COAD -0.63; TCGA ESCA -0.304; TCGA HNSC -0.351; TCGA LGG -0.116; TCGA LUSC -0.365; TCGA PAAD -0.14; TCGA SARC -0.167; TCGA THCA -0.153; TCGA STAD -0.342 |
hsa-miR-222-3p | LIFR | 12 cancers: CESC; COAD; ESCA; HNSC; KIRC; LGG; LIHC; LUAD; LUSC; PAAD; THCA; STAD | miRNATAP | TCGA CESC -0.317; TCGA COAD -0.887; TCGA ESCA -0.424; TCGA HNSC -0.473; TCGA KIRC -0.3; TCGA LGG -0.111; TCGA LIHC -0.428; TCGA LUAD -0.239; TCGA LUSC -0.388; TCGA PAAD -0.308; TCGA THCA -0.571; TCGA STAD -0.542 |
hsa-miR-222-3p | SUSD5 | 11 cancers: CESC; COAD; ESCA; HNSC; LGG; LUSC; OV; PAAD; SARC; THCA; STAD | miRNATAP | TCGA CESC -0.39; TCGA COAD -0.98; TCGA ESCA -0.45; TCGA HNSC -0.539; TCGA LGG -0.306; TCGA LUSC -0.683; TCGA OV -0.168; TCGA PAAD -0.278; TCGA SARC -0.293; TCGA THCA -0.35; TCGA STAD -0.656 |
hsa-miR-222-3p | REV3L | 15 cancers: CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUSC; OV; PAAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA CESC -0.263; TCGA COAD -0.243; TCGA ESCA -0.141; TCGA HNSC -0.129; TCGA KIRC -0.134; TCGA KIRP -0.125; TCGA LGG -0.092; TCGA LIHC -0.103; TCGA LUSC -0.21; TCGA OV -0.113; TCGA PAAD -0.298; TCGA SARC -0.204; TCGA THCA -0.068; TCGA STAD -0.24; TCGA UCEC -0.157 |
hsa-miR-222-3p | TIMP3 | 9 cancers: COAD; ESCA; HNSC; KIRC; LGG; LIHC; LUSC; THCA; STAD | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | TCGA COAD -0.496; TCGA ESCA -0.696; TCGA HNSC -0.276; TCGA KIRC -0.325; TCGA LGG -0.136; TCGA LIHC -0.196; TCGA LUSC -0.744; TCGA THCA -0.229; TCGA STAD -0.462 |
hsa-miR-222-3p | PLSCR4 | 10 cancers: COAD; HNSC; KIRC; KIRP; LIHC; LUSC; PAAD; SARC; THCA; STAD | MirTarget | TCGA COAD -0.308; TCGA HNSC -0.131; TCGA KIRC -0.272; TCGA KIRP -0.166; TCGA LIHC -0.328; TCGA LUSC -0.366; TCGA PAAD -0.289; TCGA SARC -0.121; TCGA THCA -0.28; TCGA STAD -0.469 |
hsa-miR-222-3p | HMBOX1 | 9 cancers: HNSC; LGG; LIHC; LUAD; LUSC; OV; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA HNSC -0.095; TCGA LGG -0.078; TCGA LIHC -0.091; TCGA LUAD -0.21; TCGA LUSC -0.109; TCGA OV -0.115; TCGA THCA -0.17; TCGA STAD -0.119; TCGA UCEC -0.153 |
Enriched cancer pathways of putative targets